Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2018
ICER final report highlights uncertainty in long-term safety and effectiveness of new treatments for hereditary transthyretin amyloidosis, discusses options for insurance coverage criteria
4 October 2018 - The ICER today released a final evidence report and report-at-a-glance on inotersen (Akcea Therapeutics) and patisiran ...
Posted by Michael Wonder on 07 Sep 2018
ICER releases draft evidence report on medications for treatment of opioid use disorder
7 September 2018 - Public comment period now open until 4 October 2018; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 30 Aug 2018
ICER finds current list price of patisiran for amyloidosis far exceeds standard cost-effectiveness levels
29 August 2018 - Report also evaluates evidence on inotersen; during public meeting of Midwest CEPAC on 13 September, a policy ...
Posted by Michael Wonder on 25 Aug 2018
ICER report finds evidence inadequate to distinguish the clinical benefits of different anti-androgen therapies for men with non-metastatic castration-resistant prostate cancer
24 August 2018 - Added costs of treating earlier stage disease with all therapies are aligned with their added clinical benefits ...
Posted by Michael Wonder on 23 Aug 2018
ICER releases draft evidence report on long-term treatments for prevention of hereditary angioedema attacks
23 August 2018 - Public comment period now open until 20 September; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 04 Aug 2018
ICER final report highlights limitations in evidence on long-term safety and effectiveness of elagolix for endometriosis, discusses options for insurance coverage criteria
3 August 2018 - Because elagolix’s price aligns with clinical benefit only when compared to no other treatment, insurers may first ...
Posted by Michael Wonder on 04 Aug 2018
ICER updated report on targeted treatments for plaque psoriasis finds guselkumab and risankizumab offer superior health benefit compared with TNFα inhibitors
3 August 2018 - Policy recommendations repeat call for insurers to minimise step therapy requirements on these treatments that are priced ...
Posted by Michael Wonder on 03 Jul 2018
ICER's final report on CGRP inhibitors for migraine prevention explores specific coverage policy options in light of responsible manufacturer pricing
3 July 2018 - Report notes the significant remaining uncertainty about the long-term safety of CGRP inhibitors given their new mechanism ...
Posted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst ...
Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount ...
Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future ...
Posted by Michael Wonder on 31 May 2018
ICER finds price of erenumab aligns with clinical benefit in patients for whom other therapies have failed to prevent migraines
31 May 2018 - Clinical benefits similar to other new CGRP inhibitors included in review. ...
Posted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 24 Mar 2018
ICER final report on CAR-T therapies highlights need for systemwide changes to ensure affordability and access to innovative, one-time therapies
23 March 2018 - Policy recommendations highlight that even though the pricing of current CAR-T therapies aligns with patient benefit ...
Posted by Michael Wonder on 15 Mar 2018
ICER finds emicizumab reduces treatment cost while improving health of people with haemophilia A
15 March 2018 - Report will be subject to public deliberation during New England CEPAC meeting on 29 March 2018. ...